ログイン

IMMUNOLOGY-SEROLOGY AND BLOOD BANKING PRE-TEST

IMMUNOLOGY-SEROLOGY AND BLOOD BANKING PRE-TEST
35問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    A few isolated aggregates; mostly free-floating cells; supernatant appears red: a. Negative b. Mixed-field ¢. Trace d. 1+

    b. Mixed-field

  • 2

    Serum amyloid A (SAA) has been found to increase significantly more in ___ infections. a. Bacterial infections b. Fungal infections c. Parasitic infections d. Viral infections

    a. Bacterial infections

  • 3

    The ALTERNATIVE complement pathway Is activated by: a. Antigen-antibody complexes b. Bacterial and fungal cell walls c. Carbohydrates in microbial cell walls d. Properdin

    b. Bacterial and fungal cell walls

  • 4

    Serum sickness, Arthus reaction and SLE: a. Type | hypersensitivity reactions b. Type Il hypersensitivity reactions c. Type lIl hypersensitivity reactions d. Type IV hypersensitivity reactions

    c. Type lIl hypersensitivity reactions

  • 5

    It is considered the gold standard in testing for contact dermatitis: a. Mantoux test b. Patch test ¢ RIST d. RAST

    b. Patch test

  • 6

    Which of the following would be considered an organ-specific autoimmune disease? a. Systemic lupus erythematosus b. Hashimoto's thyroiditis c. Granulomatosis with polyangiitis (Wegener's granulomatosis) d. Rheumatoid arthritis

    b. Hashimoto's thyroiditis

  • 7

    :Most Specific for SLE, because they are mainly seen only in patients with lupus, and levels correlate with disease activity: a. Anti-DNP b. Anti-RNP c. Anti-dsDNA d. Anti-Smith

    c. Anti-dsDNA

  • 8

    Anti-glomerular basement membrane antlbody Is most often assoclated with this condition: a. Systemic lupus erythematosus b. Chronic active hepatitis c. Celiac disease d. Goodpasture disease

    d. Goodpasture disease

  • 9

    In primary biliary cirrhosis, which of the following antibodies Is seen in high titers? a. Anti-mitochondrial b. Anti-smooth muscle ¢. Anti-DNA d. Anti-parietal cell

    a. Anti-mitochondrial

  • 10

    In chronic active hepatitis, high titers of which of the following antibodles are seen? a. Anti-mitochondrial b. Anti-smooth muscle ¢. Anti-DNA d. Anti-parietal cell

    b. Anti-smooth muscle

  • 11

    Primary antibody found in Helicobacter pylori infection: a. IgA b. IgE ¢.IgG d. IgM

    ¢.IgG

  • 12

    Current recommendations Include the combined detection of mannan and anti-mannan antibodies for the specific identification of species in serum samples: " a. Bordetella b. Candida c. Cryptococcus d. Mycobacterium

    b. Candida

  • 13

    Tests to identify infection with HIV fall into which three general classification types of tests? a. Tissue culture, antigen, and antibody tests b. Tests for antigens, antibodies, and nucleic acid c. DNA probe, DNA amplification, and Western blot tests d. ELISA, Western blot, and Southern blot tests

    b. Tests for antigens, antibodies, and nucleic acid

  • 14

    Interpret the following results for HIV infection. ELISA positve Repeat ELISA: negative Western Blot: No bands a. Positive for HIV b. Negative for HIV c. Indeterminate d. Further testing needed

    b. Negative for HIV

  • 15

    A 55-year-old male with early stage prostate cancer diagnosed by biopsy had his prostate gland removed (simple prostatectomy). His PSA prior to surgery was 10.0 ng/mL. If the surgery was successful in completely removing the tumor cells, what would the PSA result be 1 month after surgery? a. Undetectable b. 1-3 ng/mL c. Less than 4 ng/mL. d. Less than 10 ng/mL

    a. Undetectable

  • 16

    patient has a prostate-specific antigen level of 60 ng/mL the day before surgery to remove a localized prostate tumor. One week following surgery, the serum PSA was determined to be 8 ng/mL by the same method. What is the most likely cause of these results? a. Incomplete removal of the malignancy b. Cross reactivity of the antibody with another tumor antigen c. Testing too soon after surgery d. Hook effect with the PSA assay

    c. Testing too soon after surgery

  • 17

    Attempts to find a nontoxic anticoagulant began in 1869, when BRAXTON HICKS recommended: a. EDTA b. Heparin c. Sodium citrate d. Sodium phosphate

    d. Sodium phosphate

  • 18

    Reported the use of sodium citrate as an anticoagulant solution for transfusions: a. Charles Drew b. Edward Lindemann c. Hustin d. Lewisohn

    c. Hustin

  • 19

    The k (Cellano) antigen is a high-frequency antigen and is found on most red cells. How often would one expect to find the corresponding antibody? a. Often, because it is a high frequency antibody b. Rarely, because most individuals have the antigen and therefore would not develop the antibody c. It depends upon the population, because certain racial and ethnic groups show a higher frequency of anti-k d. Impossible to determine without consulting regional blood group antigen charts

    b. Rarely, because most individuals have the antigen and therefore would not develop the antibody

  • 20

    The antigen was reported in 1973 and is present on RBCs of 4% of Indians, 11% of Iranians, and 12% of Arabs: a. Cromer b. Diego c. Indian d. Knops

    c. Indian

  • 21

    Treatment with this drug is a cause of permanent donor deferral: a. Accutane b. Propecia ¢. Proscar d. Tegison

    d. Tegison

  • 22

    Which of the following vaccinations carries no deferral period? a. Rubella b. Varicella zoster ¢. Recombinant HPV d. Smallpox

    ¢. Recombinant HPV

  • 23

    Frozen plasma stored at -65 °C: a. 1year b. 2 years c. 7 years d. 10 years

    c. 7 years

  • 24

    What component is most frequently involved with transfusion-associated sepsis? a. Plasma b. Packed red blood cells ¢. Platelets d. Whole blood

    ¢. Platelets

  • 25

    The most serious hemolytic transfusion reactions are due to incompatibility in which of the following blood group systems? a. ABO b. Rh ¢.MN d. Duffy

    a. ABO

  • 26

    A post-transfusion to pre-transfusion brain natriuretic peptide (BNP) ratio of ___ provides diagnosis of transfusion-associated circulatory overload (TACO): v a. 0.5 b.1.5 ¢.3.0 d. 4.5

    b.1.5

  • 27

    Posttransfusion hepatitis of unknown etiology; may be transmitted by parenteral exposure to blood, fecal-oral route and from mother to child: a. HIV b. HBV c. HGV d.TTV

    d.TTV

  • 28

    The most important serologic test for diagnosing HDFN is the DAT with anti-lgG reagent. What is the specimen for a. Infant's serum or plasma b. Infant's RBCs ’ c. Mothers serum or plasma d. Mothers RBCs ’

    b. Infant's RBCs ’

  • 29

    :the simplest type of mutation and includes substitutions, insertions, and deletions: . a. Frameshift mutation b. Missense mutation c. Nonsense mutation d. Point mutation

    d. Point mutation

  • 30

    Acetylcholine-receptor blocking antibodies

    MYASTHENIA GRAVIS

  • 31

    Anti-myelin antibodies

    MULTIPLE SCLEROSIS

  • 32

    Anti-mitochondrial antibodies

    PRIMARY BILIARY CIRRHOSIS

  • 33

    Anti-smooth muscle antibodies

    CHRONIC ACTIVE HEPATITIS

  • 34

    Anti-thyroglobulin, anti-microsomal (anti-thyroid peroxidase, TPO) antibodies

    HASHIMOTO'S THYROIDITIS

  • 35

    Anti-TSH receptor antibodies

    GRAVES' DISEASE

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    A few isolated aggregates; mostly free-floating cells; supernatant appears red: a. Negative b. Mixed-field ¢. Trace d. 1+

    b. Mixed-field

  • 2

    Serum amyloid A (SAA) has been found to increase significantly more in ___ infections. a. Bacterial infections b. Fungal infections c. Parasitic infections d. Viral infections

    a. Bacterial infections

  • 3

    The ALTERNATIVE complement pathway Is activated by: a. Antigen-antibody complexes b. Bacterial and fungal cell walls c. Carbohydrates in microbial cell walls d. Properdin

    b. Bacterial and fungal cell walls

  • 4

    Serum sickness, Arthus reaction and SLE: a. Type | hypersensitivity reactions b. Type Il hypersensitivity reactions c. Type lIl hypersensitivity reactions d. Type IV hypersensitivity reactions

    c. Type lIl hypersensitivity reactions

  • 5

    It is considered the gold standard in testing for contact dermatitis: a. Mantoux test b. Patch test ¢ RIST d. RAST

    b. Patch test

  • 6

    Which of the following would be considered an organ-specific autoimmune disease? a. Systemic lupus erythematosus b. Hashimoto's thyroiditis c. Granulomatosis with polyangiitis (Wegener's granulomatosis) d. Rheumatoid arthritis

    b. Hashimoto's thyroiditis

  • 7

    :Most Specific for SLE, because they are mainly seen only in patients with lupus, and levels correlate with disease activity: a. Anti-DNP b. Anti-RNP c. Anti-dsDNA d. Anti-Smith

    c. Anti-dsDNA

  • 8

    Anti-glomerular basement membrane antlbody Is most often assoclated with this condition: a. Systemic lupus erythematosus b. Chronic active hepatitis c. Celiac disease d. Goodpasture disease

    d. Goodpasture disease

  • 9

    In primary biliary cirrhosis, which of the following antibodies Is seen in high titers? a. Anti-mitochondrial b. Anti-smooth muscle ¢. Anti-DNA d. Anti-parietal cell

    a. Anti-mitochondrial

  • 10

    In chronic active hepatitis, high titers of which of the following antibodles are seen? a. Anti-mitochondrial b. Anti-smooth muscle ¢. Anti-DNA d. Anti-parietal cell

    b. Anti-smooth muscle

  • 11

    Primary antibody found in Helicobacter pylori infection: a. IgA b. IgE ¢.IgG d. IgM

    ¢.IgG

  • 12

    Current recommendations Include the combined detection of mannan and anti-mannan antibodies for the specific identification of species in serum samples: " a. Bordetella b. Candida c. Cryptococcus d. Mycobacterium

    b. Candida

  • 13

    Tests to identify infection with HIV fall into which three general classification types of tests? a. Tissue culture, antigen, and antibody tests b. Tests for antigens, antibodies, and nucleic acid c. DNA probe, DNA amplification, and Western blot tests d. ELISA, Western blot, and Southern blot tests

    b. Tests for antigens, antibodies, and nucleic acid

  • 14

    Interpret the following results for HIV infection. ELISA positve Repeat ELISA: negative Western Blot: No bands a. Positive for HIV b. Negative for HIV c. Indeterminate d. Further testing needed

    b. Negative for HIV

  • 15

    A 55-year-old male with early stage prostate cancer diagnosed by biopsy had his prostate gland removed (simple prostatectomy). His PSA prior to surgery was 10.0 ng/mL. If the surgery was successful in completely removing the tumor cells, what would the PSA result be 1 month after surgery? a. Undetectable b. 1-3 ng/mL c. Less than 4 ng/mL. d. Less than 10 ng/mL

    a. Undetectable

  • 16

    patient has a prostate-specific antigen level of 60 ng/mL the day before surgery to remove a localized prostate tumor. One week following surgery, the serum PSA was determined to be 8 ng/mL by the same method. What is the most likely cause of these results? a. Incomplete removal of the malignancy b. Cross reactivity of the antibody with another tumor antigen c. Testing too soon after surgery d. Hook effect with the PSA assay

    c. Testing too soon after surgery

  • 17

    Attempts to find a nontoxic anticoagulant began in 1869, when BRAXTON HICKS recommended: a. EDTA b. Heparin c. Sodium citrate d. Sodium phosphate

    d. Sodium phosphate

  • 18

    Reported the use of sodium citrate as an anticoagulant solution for transfusions: a. Charles Drew b. Edward Lindemann c. Hustin d. Lewisohn

    c. Hustin

  • 19

    The k (Cellano) antigen is a high-frequency antigen and is found on most red cells. How often would one expect to find the corresponding antibody? a. Often, because it is a high frequency antibody b. Rarely, because most individuals have the antigen and therefore would not develop the antibody c. It depends upon the population, because certain racial and ethnic groups show a higher frequency of anti-k d. Impossible to determine without consulting regional blood group antigen charts

    b. Rarely, because most individuals have the antigen and therefore would not develop the antibody

  • 20

    The antigen was reported in 1973 and is present on RBCs of 4% of Indians, 11% of Iranians, and 12% of Arabs: a. Cromer b. Diego c. Indian d. Knops

    c. Indian

  • 21

    Treatment with this drug is a cause of permanent donor deferral: a. Accutane b. Propecia ¢. Proscar d. Tegison

    d. Tegison

  • 22

    Which of the following vaccinations carries no deferral period? a. Rubella b. Varicella zoster ¢. Recombinant HPV d. Smallpox

    ¢. Recombinant HPV

  • 23

    Frozen plasma stored at -65 °C: a. 1year b. 2 years c. 7 years d. 10 years

    c. 7 years

  • 24

    What component is most frequently involved with transfusion-associated sepsis? a. Plasma b. Packed red blood cells ¢. Platelets d. Whole blood

    ¢. Platelets

  • 25

    The most serious hemolytic transfusion reactions are due to incompatibility in which of the following blood group systems? a. ABO b. Rh ¢.MN d. Duffy

    a. ABO

  • 26

    A post-transfusion to pre-transfusion brain natriuretic peptide (BNP) ratio of ___ provides diagnosis of transfusion-associated circulatory overload (TACO): v a. 0.5 b.1.5 ¢.3.0 d. 4.5

    b.1.5

  • 27

    Posttransfusion hepatitis of unknown etiology; may be transmitted by parenteral exposure to blood, fecal-oral route and from mother to child: a. HIV b. HBV c. HGV d.TTV

    d.TTV

  • 28

    The most important serologic test for diagnosing HDFN is the DAT with anti-lgG reagent. What is the specimen for a. Infant's serum or plasma b. Infant's RBCs ’ c. Mothers serum or plasma d. Mothers RBCs ’

    b. Infant's RBCs ’

  • 29

    :the simplest type of mutation and includes substitutions, insertions, and deletions: . a. Frameshift mutation b. Missense mutation c. Nonsense mutation d. Point mutation

    d. Point mutation

  • 30

    Acetylcholine-receptor blocking antibodies

    MYASTHENIA GRAVIS

  • 31

    Anti-myelin antibodies

    MULTIPLE SCLEROSIS

  • 32

    Anti-mitochondrial antibodies

    PRIMARY BILIARY CIRRHOSIS

  • 33

    Anti-smooth muscle antibodies

    CHRONIC ACTIVE HEPATITIS

  • 34

    Anti-thyroglobulin, anti-microsomal (anti-thyroid peroxidase, TPO) antibodies

    HASHIMOTO'S THYROIDITIS

  • 35

    Anti-TSH receptor antibodies

    GRAVES' DISEASE